Investigational Drug Information for rilzabrutinib

What is the drug development status for rilzabrutinib?

rilzabrutinib is an investigational drug.

There have been 8 clinical trials for rilzabrutinib. The most recent clinical trial was a Phase 1 trial, which was initiated on December 14^th 2020.

The most common disease conditions in clinical trials are Eczema, Thrombocytopenia, and Dermatitis, Atopic. The leading clinical trial sponsors are Sanofi, Principia Biopharma, a Sanofi Company, and Principia Biopharma Inc.

There is one US patent protecting this investigational drug and thirty-seven international patents.

Summary for rilzabrutinib

US Patents	1
International Patents	37
US Patent Applications	5
WIPO Patent Applications	7
Japanese Patent Applications	1
Clinical Trial Progress	Phase 1 (2020-12-14)
Vendors	35

Recent Clinical Trials for rilzabrutinib

Title	Sponsor	Phase
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma	Sanofi	Phase 2
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to Omalizumab	Sanofi	Phase 2
Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)	Sanofi	Phase 2

See all rilzabrutinib clinical trials

Clinical Trial Summary for rilzabrutinib

Top disease conditions for rilzabrutinib

Top clinical trial sponsors for rilzabrutinib

See all rilzabrutinib clinical trials

US Patents for rilzabrutinib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
rilzabrutinib		Pyrazolopyrimidine compounds as kinase inhibitors	Principia Biopharma Inc. (South San Francisco, CA)

International Patents for rilzabrutinib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
rilzabrutinib	Australia	AU2013312296	2032-09-10
rilzabrutinib	Brazil	BR112015003859	2032-09-10
rilzabrutinib	Canada	CA2882367	2032-09-10
rilzabrutinib	China	CN104822681	2032-09-10